BioMarin reports record FY2023 revenue $2.42B (+15% YoY); non-GAAP EPS $2.08 (+36% YoY)

BIOMARIN PHARMACEUTICAL INC

2023-FY EPS reported $0.87 revenue$2,419,226,000

FY2023 total revenues $2.42B (+15% YoY); GAAP diluted EPS $0.87 (+16% YoY); non-GAAP diluted EPS $2.08 (+36% YoY).
VOXZOGO net revenues $146M in Q4'23 (+118% Q/Q) and $470M for FY'23 (+178% YoY); 2,613 children treated at year-end.
Q4'23 total revenues $646.2M (+20% YoY); GAAP net income $20.4M vs $0.2M loss in Q4'22.
2024 guidance: double-digit total revenue growth, non-GAAP operating margin expansion, EPS growing faster than revenue.
FDA approved VOXZOGO for children under 5; ~70% of new US starts from that age group in Q4'23.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

BIOMARIN PHARMACEUTICAL INC reported fourth quarter and full year ended December 31, 2023 results: revenue $646.2 million, net income $20.4 million, EPS $0.11. Guidance reaffirmed.

Period: fourth quarter and full year ended December 31, 2023
Revenue: $646.2 million
Net income: $20.4 million
EPS: $0.11
Guidance: reaffirmed
Result: reported results

Exact text from the filing

plans and convertible debt in periods when they are dilutive under Non-GAAP. nm Not meaningful Financial Highlights: • Total Revenues for the fourth quarter of 2023 were $646.2 million, an increase of 20% compared to the same period in 2022. The increase in Total Revenues was primarily attributed to higher VOXZOGO sales volume driven by new patients initiating

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001048477-24-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.